Bioxcel Therapeutics' 15min chart shows RSI overbought, Bollinger Bands expanding downward.

According to Bioxcel Therapeutics's 15-minute chart, the Relative Strength Index (RSI) has reached overbought levels and the Bollinger Bands are expanding downward as of September 10, 2025, at 11:30. This suggests that the stock price has risen too quickly and is now unsupported by fundamental values, indicating that the market trend is being driven by selling pressure.

BioXcel Therapeutics (NASDAQ: BTAI) saw its stock price rise rapidly, reaching overbought levels on the Relative Strength Index (RSI) and expanding Bollinger Bands downward as of September 10, 2025, at 11:30 [^NUMBER]. This technical analysis suggests that the stock price has surged too quickly, potentially indicating unsupported fundamentals and selling pressure.

During the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, BioXcel CEO Vimal Mehta presented the company's strategic focus on expanding IGALMI, a treatment for agitation in schizophrenia and bipolar disorder. Mehta emphasized the promising potential of IGALMI in home settings, despite challenges in commercialization and regulatory steps ahead.

Key takeaways from the presentation include:
- BioXcel is expanding IGALMI's use to home settings, targeting a larger market.
- The SERENITY At-Home trial showed IGALMI's safety in a home setting.
- An sNDA for IGALMI's home use is expected in Q1 2026.
- BioXcel is pursuing an Alzheimer's agitation treatment, with a second Phase 3 trial planned.

These updates suggest a positive outlook for BioXcel, but the stock's technical indicators point to a potential correction. Investors should remain vigilant and consider the broader market context when evaluating BioXcel's stock performance.